AUPH
Aurinia Pharmaceuticals Inc.
AUPH offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over AUPH overall, supported by stronger modeled upside and lower modeled downside.
AUPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
AUPH's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AUPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.1x | $16.18 | -0.2% |
| Current | 7.1x | $16.21 | — |
| Forward | 19x | $16.21 | — |
| Fair | 26x | $59.75 | +269% |
| Expensive | 31x | $70.12 | +333% |
Historical ranges are pointers, not guarantees.
AUPH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AUPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect AUPH's revenue to grow, but its profitability to weaken.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AUPH on the outlook, with more favorable valuation and earnings expectations.
AUPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.83 | -64% |
| Q3 2026 | $2.29 | +309% |
| Q2 2026 | $2.29 | +433% |
| Q1 2026 | $2.17 | +675% |
| Q4 2025 | $2.08 | +4060% |
| Q3 2025 | $0.56 | +$0.71 |
| Q2 2025 | $0.43 | +$0.77 |
| Q1 2025 | $0.28 | +$0.71 |
| Q4 2024 | $0.05 | +$0.59 |
AUPH's earnings per share have climbed steadily: $2.29 over the past year, about four times what it earned the year before, and higher year over year for 17 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
AUPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.7M | +14% |
| Q2 2026 | $83.2M | +19% |
| Q1 2026 | $77.7M | +24% |
| Q4 2025 | $77.1M | +29% |
| Q3 2025 | $73.5M | +8.4% |
| Q2 2025 | $70M | +22% |
| Q1 2025 | $62.5M | +24% |
| Q4 2024 | $59.9M | +33% |
AUPH's revenue has grown year over year for 12 quarters in a row: $84M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | +1.8 points |
| Q2 2026 | 56% | +27 points |
| Q1 2026 | 53% | +18 points |
| Q4 2025 | 43% | +46 points |
| Q3 2025 | 40% | +23 points |
| Q2 2025 | 29% | +31 points |
| Q1 2025 | 35% | +61 points |
| Q4 2024 | -2.8% | +63 points |
AUPH has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AUPH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
AUPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | +4.3% |
| Q2 2026 | $52.6M | +19% |
| Q1 2026 | $32.6M | +2405% |
| Q4 2025 | $45.7M | +52% |
| Q3 2025 | $44.4M | +161% |
| Q2 2025 | $44.2M | +179% |
| Q1 2025 | $1.3M | +$19.9M |
| Q4 2024 | $30.1M | +110% |
AUPH has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
AUPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | -0.6% | -835K shares |
| 3 years | -5.4% | -7.7M shares |
| 5 years | +5.2% | +6.7M shares |
| Available history | +38% | +37.2M shares |
AUPH has 135M diluted shares, down 0.6% from a year ago, with $75M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $38.7M |
| Q1 2026 | $36.2M |
| Q4 2025 | — |
| Q3 2025 | $8.7M |
| Q2 2025 | $42.6M |
| Q1 2025 | $46.9M |
| Q4 2024 | $21.8M |
AUPH spent $75M buying back its own shares over the past year, down 38% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AUPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
AUPH has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AUPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.9 | Neutral |
| Stochastic | 57.0 | Neutral |
AUPH's weekly RSI is 52 (neutral) and its Stochastic is 57 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AUPH PE vs Healthcare Sector
| Metric | AUPH | Sector median | Relative |
|---|---|---|---|
| PE | 7.1x | 26x | 73% below |
| PE % | 18 | 29 | 11 pts below |
AUPH has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AUPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.5 | 1.5% below |
| 20 week MA | $16.1 | 0.5% above |
| 50 week MA | $15.6 | 3.9% above |
| 100 week MA | $12.7 | 27% above |
| 200 week MA | $10.3 | 57% above |
AUPH's trend is up, with a small recent dip: it's below only its 8-week average, and 57% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AUPH on trend strength, trading above more of its moving averages.
AUPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.4 | $14.2 | -34% |
| 2021 | $14.2 | $23.1 | +63% |
| 2022 | $23.1 | $4.53 | -80% |
| 2023 | $4.53 | $8.99 | +98% |
| 2024 | $8.99 | $9.20 | +2.3% |
| 2025 | $9.20 | $16.3 | +77% |
| 2026 YTD | $16.3 | $16.2 | -0.2% |
AUPH has finished higher in four of the last six years, three of them by more than 50%. It's roughly flat so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AUPH on returns for 2026, with the stronger performance.